Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition

BACKGROUND: Immunotherapy, in particular checkpoint blockade, has changed the clinical landscape of metastatic melanoma. Nonetheless, the majority of patients will either be primary refractory or progress over follow up. Management of patients progressing on first-line immunotherapy remains challeng...

Descripción completa

Detalles Bibliográficos
Autores principales: Blake, Zoë, Marks, Douglas K., Gartrell, Robyn D., Hart, Thomas, Horton, Patti, Cheng, Simon K., Taback, Bret, Horst, Basil A., Saenger, Yvonne M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887256/
https://www.ncbi.nlm.nih.gov/pubmed/29622046
http://dx.doi.org/10.1186/s40425-018-0338-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887256/
https://www.ncbi.nlm.nih.gov/pubmed/29622046
http://dx.doi.org/10.1186/s40425-018-0338-6

Ejemplares similares